NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Allink Biotherapeutics

Allink Biotherapeutics

Private
ShanghaiHealthcare & Life Scienceshttp://allinkbio.com/

Last Round

Series A

Extension

Dec 16, 2025

Total Funding Raised

$159.5M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Allink Biotherapeutics is a biotechnology company that develops a pipeline of First-in-Class and Best-in-Class antibody-drug conjugates and multispecific antibody therapeutics for oncology and immunology diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service

AI Layer

Non-AI

Keywords

antibody-drug conjugatesADCbispecific antibodyT-cell engagerTCEoncology therapeuticssolid tumor immunotherapybiotech drug discoveryclinical-stage biotechantibody engineeringbiopharma licensingtargeted cancer therapynext-gen biologicsdrug pipeline

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Allink Biotherapeutics Comps

Public and private peers based on sector, stage, and business model.

Allink Biotherapeutics comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Allink Biotherapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series A ExtensionDec 16, 2025
Series ANov 28, 2024

Key People

Founding team and executive leadership

Hui Feng

Chief Executive Officer

Executive Team

Allink Biotherapeutics Investors

Notable investors and investment history

Allink Biotherapeutics investors
InvestorRounds
Lanchi VenturesSeries A Extension, Series A
YuanBio Venture CapitalSeries A Extension, Series A
Lapam CapitalSeries A Extension
Legend CapitalSeries A, Series A Extension
5Y CapitalSeries A Extension
C&D Emerging Industry Equity InvestmentSeries A
Medfine CapitalSeries A, Angel

Market signals

Structured signals derived from secondary market and firmographic data.

  • Dec 16, 2025

    $47M raised in Series A Extension round.

  • Nov 28, 2024

    $42M round led by Lanchi Ventures

Allink Biotherapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Allink Biotherapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Allink Biotherapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersShanghai
Employee Range9
Year Founded2023
Last FundingDec 16, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.